Relevance of the basophil activation test in a cohort of 240 patients with chronic spontaneous urticaria
Clinical and Experimental Dermatology · 24.02.2025 · 50 (3) · 551-557
DOI: 10.1093/ced/llae441 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Dermatology, online erschienen am 16.10.2024. Verfasst von David Pesqué und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Hospital del Mar Research Institute, Barcelona, Spain. Hauptthemen laut MEDLINE: Chronic Urticaria, Basophils, Basophil Degranulation Test. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 32 Literaturangaben.
Abstract (Originalsprache)
Background
The basophil activation test (BAT) is considered to be the best biomarker to predict autoimmune chronic spontaneous urticaria (aiCSU). To date, few studies have investigated the utility of BAT in real-world clinical practice, the role of aiCSU biomarkers in relation to omalizumab therapy and the degree of association between different aiCSU tests.
Objectives
To analyse the clinical and laboratory features of a prospective cohort with chronic spontaneous urticaria (CSU) according to their BAT status, as well as to study omalizumab efficacy according to aiCSU biomarkers.
Methods
A prospective study was conducted from 2010 to 2024 in patients with CSU. BAT alongside other laboratory tests were performed, and clinical and therapeutic features were prospectively collected. Data obtained were compared according to BAT status (positive vs. negative). Furthermore, omalizumab drug survival was typified according to aiCSU biomarkers.
Results
In total, 240 patients were included in the study. Patients who were BAT positive presented more frequently with low IgE levels, higher occurrence of IgG antithyroid peroxidase (anti-TPO) positivity, autologous serum skin test (ASST) positivity, basopenia and eosinopenia. Multivariate logistic regression revealed that ASST [odds ratio (OR) 7.69, 95% confidence interval (CI) 2.81–21.0] and anti-TPO (OR 2.63, 95% CI 1.05–6.61) were associated with BAT positivity. All aiCSU biomarkers (BAT, ASST, combined ASST/BAT positivity and low IgE/anti-TPO+) were associated with significantly shorter omalizumab survival because of treatment failure. In the cohort, both low IgE/anti-TPO+ and ASST were associated with BAT positivity.
Conclusions
The use of BAT in clinical practice delineates a subgroup of patients with specific clinical, laboratory and therapeutic features, including increased omalizumab failure.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Hospital del Mar Research Institute, Barcelona, Spain.
- Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.
- Department of Immunology, Hospital del Mar Research Institute, Barcelona, Spain.
- Universitat Pompeu Fabra (UPF), Barcelona, Spain.
ORCID-Profile: David Pesqué, Ana M Giménez-Arnau
Zitieren
APA
Pesqué, D., Andrades, E., Torres-Bosó, P., Soto, D., Gimeno, R., Pujol, R. M., Yélamos, J., & Giménez-Arnau, A. M. (2025). Relevance of the basophil activation test in a cohort of 240 patients with chronic spontaneous urticaria. Clinical and Experimental Dermatology, 50(3), 551-557. https://doi.org/10.1093/ced/llae441
Vancouver
Pesqué D, Andrades E, Torres-Bosó P, Soto D, Gimeno R, Pujol RM, et al. Relevance of the basophil activation test in a cohort of 240 patients with chronic spontaneous urticaria. Clinical and Experimental Dermatology. 2025;50(3):551-557. doi:10.1093/ced/llae441
BibTeX
@article{Pesqu2025,
author = {Pesqué, David and Andrades, Evelyn and Torres-Bosó, Paloma and Soto, Dulce and Gimeno, Ramon and Pujol, Ramon M and Yélamos, José and Giménez-Arnau, Ana M},
title = {Relevance of the basophil activation test in a cohort of 240 patients with chronic spontaneous urticaria},
journal = {Clinical and Experimental Dermatology},
year = {2025},
volume = {50},
number = {3},
pages = {551--557},
doi = {10.1093/ced/llae441}
}
EUVIMED